Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae032 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von A Swaminathan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, Biomarkers, Peroxidase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Royal Australasian College of Physicians, New Zealand Society of Gastroenterology Research.
Abstract (Originalsprache)
Background
Biomarkers have been proposed as surrogate treatment targets for the management of inflammatory bowel disease (IBD); however, their relationship with IBD-related complications remains unclear. This study investigated the utility of neutrophil biomarkers fecal calprotectin (fCal) and fecal myeloperoxidase (fMPO) in predicting a complicated IBD course.
Methods
Participants with IBD were followed for 24 months to assess for a complicated IBD course (incident corticosteroid use, medication escalation for clinical disease relapse, IBD-related hospitalizations/surgeries). Clinically active IBD was defined as Harvey-Bradshaw index >4 for Crohn’s disease (CD) and simple clinical colitis activity index >5 for ulcerative colitis (UC). Area under the receiver-operating-characteristics curves (AUROC) and multivariable logistic regression assessed the performance of baseline symptom indices, fCal, and fMPO in predicting a complicated disease IBD course at 24 months.
Results
One hundred and seventy-one participants were included (CD, n = 99; female, n = 90; median disease duration 13 years [interquartile range, 5-22]). Baseline fCal (250 μg/g; AUROC = 0.77; 95% confidence interval [CI], 0.69-0.84) and fMPO (12 μg/g; AUROC = 0.77; 95% CI, 0.70-0.84) predicted a complicated IBD course. Fecal calprotectin (adjusted OR = 7.85; 95% CI, 3.38-18.26) and fMPO (adjusted OR = 4.43; 95% CI, 2.03-9.64) were associated with this end point after adjustment for other baseline variables including clinical disease activity. C-reactive protein (CRP) was inferior to fecal biomarkers and clinical symptoms (pdifference < .05) at predicting a complicated IBD course. A combination of baseline CRP, fCal/fMPO, and clinical symptoms provided the greatest precision at identifying a complicated IBD course.
Conclusions
Fecal biomarkers are independent predictors of IBD-related outcomes and are useful adjuncts to routine clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
- Department of Gastroenterology, Christchurch Hospital, New Zealand.
- Mātai Hāora, Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.
- Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand.
ORCID-Profile: A Swaminathan, A S Day
Förderung
- Royal Australasian College of Physicians
- New Zealand Society of Gastroenterology Research
Zitieren
APA
Swaminathan, A., Borichevsky, G. M., Frampton, C. M., Day, A. S., Hampton, M. B., Kettle, A. J., & Gearry, R. B. (2025). Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae032
Vancouver
Swaminathan A, Borichevsky GM, Frampton CM, Day AS, Hampton MB, Kettle AJ, et al. Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae032
BibTeX
@article{Swaminathan2025,
author = {Swaminathan, A and Borichevsky, G M and Frampton, C M and Day, A S and Hampton, M B and Kettle, A J and Gearry, R B},
title = {Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae032}
}
EUVIMED